ID   NEK7_HUMAN              Reviewed;         302 AA.
AC   Q8TDX7; A6NGT8;
DT   03-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 1.
DT   12-OCT-2022, entry version 174.
DE   RecName: Full=Serine/threonine-protein kinase Nek7;
DE            EC=2.7.11.1;
DE   AltName: Full=Never in mitosis A-related kinase 7;
DE            Short=NimA-related protein kinase 7;
GN   Name=NEK7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=11701951; DOI=10.1159/000048779;
RA   Kimura M., Okano Y.;
RT   "Identification and assignment of the human NIMA-related protein kinase 7
RT   gene (NEK7) to human chromosome 1q31.3.";
RL   Cytogenet. Cell Genet. 94:33-38(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Pancreatic islet;
RA   Melton D., Meadows A., Clifton S., Hillier L., Marra M., Pape D., Wylie T.,
RA   Martin J., Blistain A., Schmitt A., Theising B., Ritter E., Ronko I.,
RA   Bennett J., Cardenas M., Gibbons M., McCann R., Cole R., Tsagareishvili R.,
RA   Williams T., Jackson Y., Bowers Y.;
RT   "WashU-Harvard pancreas EST project.";
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   PHOSPHORYLATION AT SER-195.
RX   PubMed=12840024; DOI=10.1074/jbc.m303663200;
RA   Belham C., Roig J., Caldwell J.A., Aoyama Y., Kemp B.E., Comb M.,
RA   Avruch J.;
RT   "A mitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the Nek6
RT   and Nek7 kinases.";
RL   J. Biol. Chem. 278:34897-34909(2003).
RN   [6]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17101132; DOI=10.1016/j.febslet.2006.10.069;
RA   Yissachar N., Salem H., Tennenbaum T., Motro B.;
RT   "Nek7 kinase is enriched at the centrosome, and is required for proper
RT   spindle assembly and mitotic progression.";
RL   FEBS Lett. 580:6489-6495(2006).
RN   [7]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17586473; DOI=10.1016/j.bbrc.2007.05.206;
RA   Kim S., Lee K., Rhee K.;
RT   "NEK7 is a centrosomal kinase critical for microtubule nucleation.";
RL   Biochem. Biophys. Res. Commun. 360:56-62(2007).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NEK9.
RX   PubMed=19414596; DOI=10.1128/mcb.01867-08;
RA   O'Regan L., Fry A.M.;
RT   "The Nek6 and Nek7 protein kinases are required for robust mitotic spindle
RT   formation and cytokinesis.";
RL   Mol. Cell. Biol. 29:3975-3990(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   SUBUNIT.
RX   PubMed=21320329; DOI=10.1186/1472-6807-11-12;
RA   Meirelles G.V., Silva J.C., Mendonca Yde A., Ramos C.H., Torriani I.L.,
RA   Kobarg J.;
RT   "Human Nek6 is a monomeric mostly globular kinase with an unfolded short N-
RT   terminal domain.";
RL   BMC Struct. Biol. 11:12-12(2011).
RN   [12]
RP   REVIEW.
RX   PubMed=17727698; DOI=10.1186/1747-1028-2-25;
RA   O'regan L., Blot J., Fry A.M.;
RT   "Mitotic regulation by NIMA-related kinases.";
RL   Cell Div. 2:25-25(2007).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-5, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   INTERACTION WITH ANKS3.
RX   PubMed=26188091; DOI=10.1016/j.bbrc.2015.07.063;
RA   Ramachandran H., Engel C., Mueller B., Dengjel J., Walz G., Yakulov T.A.;
RT   "Anks3 alters the sub-cellular localization of the Nek7 kinase.";
RL   Biochem. Biophys. Res. Commun. 464:901-907(2015).
RN   [16]
RP   FUNCTION.
RX   PubMed=26642356; DOI=10.1038/ni.3333;
RA   Shi H., Wang Y., Li X., Zhan X., Tang M., Fina M., Su L., Pratt D.,
RA   Bu C.H., Hildebrand S., Lyon S., Scott L., Quan J., Sun Q., Russell J.,
RA   Arnett S., Jurek P., Chen D., Kravchenko V.V., Mathison J.C., Moresco E.M.,
RA   Monson N.L., Ulevitch R.J., Beutler B.;
RT   "NLRP3 activation and mitosis are mutually exclusive events coordinated by
RT   NEK7, a new inflammasome component.";
RL   Nat. Immunol. 17:250-258(2016).
RN   [17]
RP   FUNCTION.
RX   PubMed=31409757; DOI=10.1126/scisignal.aaw2939;
RA   Adib R., Montgomery J.M., Atherton J., O'Regan L., Richards M.W.,
RA   Straatman K.R., Roth D., Straube A., Bayliss R., Moores C.A., Fry A.M.;
RT   "Mitotic phosphorylation by NEK6 and NEK7 reduces the microtubule affinity
RT   of EML4 to promote chromosome congression.";
RL   Sci. Signal. 12:0-0(2019).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS), DOMAIN, ACTIVITY REGULATION, AND
RP   MUTAGENESIS OF TYR-28; LEU-31; ASN-33 AND TYR-97.
RX   PubMed=19941817; DOI=10.1016/j.molcel.2009.09.038;
RA   Richards M.W., O'Regan L., Mas-Droux C., Blot J.M., Cheung J., Hoelder S.,
RA   Fry A.M., Bayliss R.;
RT   "An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase
RT   is released through binding of Nek9.";
RL   Mol. Cell 36:560-570(2009).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-35 AND MET-275.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein kinase which plays an important role in mitotic cell
CC       cycle progression (PubMed:17101132). Required for microtubule
CC       nucleation activity of the centrosome, robust mitotic spindle formation
CC       and cytokinesis (PubMed:17586473, PubMed:19414596). Phosphorylates
CC       RPS6KB1 (By similarity). Phosphorylates EML4 at 'Ser-146', promoting
CC       its dissociation from microtubules during mitosis which is required for
CC       efficient chromosome congression (PubMed:31409757). Essential protein
CC       for NLRP3 inflammasome assembly and activation that acts downstream
CC       stimuli such as K(+) efflux. Dispensable for the induction of core
CC       inflammasome components, but necessary for subsequent formation of the
CC       NLRP3:PYCARD complex, and activation of CASP1. Serves as a cellular
CC       switch that enforces mutual exclusivity of the inflammasome response
CC       and cell division. Exerts its effects on the NLRP3 inflammasome
CC       independently of its kinase activity (PubMed:26642356).
CC       {ECO:0000250|UniProtKB:D3ZBE5, ECO:0000269|PubMed:17101132,
CC       ECO:0000269|PubMed:17586473, ECO:0000269|PubMed:19414596,
CC       ECO:0000269|PubMed:26642356, ECO:0000269|PubMed:31409757}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Binding to NEK9 stimulates its activity by
CC       releasing the autoinhibitory function of Tyr-97.
CC       {ECO:0000269|PubMed:19941817}.
CC   -!- SUBUNIT: Monomer (PubMed:21320329). Interacts with NEK9
CC       (PubMed:19414596). Interacts with ANKS3; this interaction alters the
CC       subcellular distribution of NEK7 by preventing its nuclear
CC       translocation (PubMed:26188091). Interacts (via N-terminus) with NLRP3
CC       (via LRR repeat domain); the interaction is required for the formation
CC       of the complex NLRP3:PYCARD, oligomerization of PYCARD and activation
CC       of CASP1 (By similarity). {ECO:0000250|UniProtKB:Q9ES74,
CC       ECO:0000269|PubMed:19414596, ECO:0000269|PubMed:21320329,
CC       ECO:0000269|PubMed:26188091}.
CC   -!- INTERACTION:
CC       Q8TDX7; Q8N1W1-4: ARHGEF28; NbExp=3; IntAct=EBI-1055945, EBI-13062134;
CC       Q8TDX7; Q8TAB5: C1orf216; NbExp=3; IntAct=EBI-1055945, EBI-747505;
CC       Q8TDX7; O94983-5: CAMTA2; NbExp=3; IntAct=EBI-1055945, EBI-10176008;
CC       Q8TDX7; O75175: CNOT3; NbExp=3; IntAct=EBI-1055945, EBI-743073;
CC       Q8TDX7; Q6UXH1-2: CRELD2; NbExp=3; IntAct=EBI-1055945, EBI-21670927;
CC       Q8TDX7; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-1055945, EBI-742054;
CC       Q8TDX7; P49184: DNASE1L1; NbExp=3; IntAct=EBI-1055945, EBI-20894690;
CC       Q8TDX7; Q8IY82: DRC7; NbExp=3; IntAct=EBI-1055945, EBI-10262896;
CC       Q8TDX7; Q99944: EGFL8; NbExp=3; IntAct=EBI-1055945, EBI-3924130;
CC       Q8TDX7; P16422: EPCAM; NbExp=3; IntAct=EBI-1055945, EBI-1171184;
CC       Q8TDX7; Q9NVM1: EVA1B; NbExp=3; IntAct=EBI-1055945, EBI-10314666;
CC       Q8TDX7; Q96GK7: FAHD2A; NbExp=3; IntAct=EBI-1055945, EBI-21647872;
CC       Q8TDX7; Q10981: FUT2; NbExp=3; IntAct=EBI-1055945, EBI-9090702;
CC       Q8TDX7; P36382: GJA5; NbExp=3; IntAct=EBI-1055945, EBI-750433;
CC       Q8TDX7; P09471: GNAO1; NbExp=3; IntAct=EBI-1055945, EBI-715087;
CC       Q8TDX7; P79483: HLA-DRB3; NbExp=3; IntAct=EBI-1055945, EBI-3910269;
CC       Q8TDX7; P14060: HSD3B1; NbExp=3; IntAct=EBI-1055945, EBI-17426018;
CC       Q8TDX7; Q7Z6Z7-2: HUWE1; NbExp=3; IntAct=EBI-1055945, EBI-10975491;
CC       Q8TDX7; O75874: IDH1; NbExp=3; IntAct=EBI-1055945, EBI-715695;
CC       Q8TDX7; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-1055945, EBI-2557660;
CC       Q8TDX7; A0JP07: KIAA1683; NbExp=3; IntAct=EBI-1055945, EBI-10171456;
CC       Q8TDX7; P26715: KLRC1; NbExp=3; IntAct=EBI-1055945, EBI-9018187;
CC       Q8TDX7; Q6P5S2: LEG1; NbExp=3; IntAct=EBI-1055945, EBI-11750531;
CC       Q8TDX7; P09382: LGALS1; NbExp=3; IntAct=EBI-1055945, EBI-1048875;
CC       Q8TDX7; O00214-2: LGALS8; NbExp=3; IntAct=EBI-1055945, EBI-12069522;
CC       Q8TDX7; P43356: MAGEA2B; NbExp=3; IntAct=EBI-1055945, EBI-5650739;
CC       Q8TDX7; Q7Z434: MAVS; NbExp=3; IntAct=EBI-1055945, EBI-995373;
CC       Q8TDX7; Q8NCR3: MFI; NbExp=3; IntAct=EBI-1055945, EBI-744790;
CC       Q8TDX7; Q8TB02: MGC39372; NbExp=3; IntAct=EBI-1055945, EBI-25834188;
CC       Q8TDX7; Q96EY8: MMAB; NbExp=3; IntAct=EBI-1055945, EBI-7825413;
CC       Q8TDX7; A2RUH7: MYBPHL; NbExp=3; IntAct=EBI-1055945, EBI-9088235;
CC       Q8TDX7; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-1055945, EBI-3446748;
CC       Q8TDX7; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-1055945, EBI-11750983;
CC       Q8TDX7; Q8NCF5-2: NFATC2IP; NbExp=3; IntAct=EBI-1055945, EBI-12305293;
CC       Q8TDX7; Q96P20: NLRP3; NbExp=4; IntAct=EBI-1055945, EBI-6253230;
CC       Q8TDX7; Q8N323: NXPE1; NbExp=3; IntAct=EBI-1055945, EBI-25834085;
CC       Q8TDX7; Q6P4D5-2: PABIR3; NbExp=3; IntAct=EBI-1055945, EBI-9091052;
CC       Q8TDX7; P00558: PGK1; NbExp=2; IntAct=EBI-1055945, EBI-709599;
CC       Q8TDX7; Q8N2W9: PIAS4; NbExp=3; IntAct=EBI-1055945, EBI-473160;
CC       Q8TDX7; Q8NBT0: POC1A; NbExp=3; IntAct=EBI-1055945, EBI-2557132;
CC       Q8TDX7; O14829: PPEF1; NbExp=3; IntAct=EBI-1055945, EBI-2931238;
CC       Q8TDX7; Q96QH2: PRAM1; NbExp=3; IntAct=EBI-1055945, EBI-2860740;
CC       Q8TDX7; Q9Y617: PSAT1; NbExp=3; IntAct=EBI-1055945, EBI-709652;
CC       Q8TDX7; P43686: PSMC4; NbExp=3; IntAct=EBI-1055945, EBI-743997;
CC       Q8TDX7; Q13200: PSMD2; NbExp=3; IntAct=EBI-1055945, EBI-357648;
CC       Q8TDX7; Q9Y3Y4: PYGO1; NbExp=3; IntAct=EBI-1055945, EBI-3397474;
CC       Q8TDX7; Q13636: RAB31; NbExp=3; IntAct=EBI-1055945, EBI-725987;
CC       Q8TDX7; Q96E17: RAB3C; NbExp=3; IntAct=EBI-1055945, EBI-4287022;
CC       Q8TDX7; P61224: RAP1B; NbExp=3; IntAct=EBI-1055945, EBI-358143;
CC       Q8TDX7; P50749: RASSF2; NbExp=3; IntAct=EBI-1055945, EBI-960081;
CC       Q8TDX7; Q96I25: RBM17; NbExp=3; IntAct=EBI-1055945, EBI-740272;
CC       Q8TDX7; P52756: RBM5; NbExp=3; IntAct=EBI-1055945, EBI-714003;
CC       Q8TDX7; Q02978: SLC25A11; NbExp=3; IntAct=EBI-1055945, EBI-359174;
CC       Q8TDX7; Q3SY56: SP6; NbExp=3; IntAct=EBI-1055945, EBI-11175533;
CC       Q8TDX7; Q96L03: SPATA17; NbExp=3; IntAct=EBI-1055945, EBI-13322423;
CC       Q8TDX7; Q7Z698: SPRED2; NbExp=3; IntAct=EBI-1055945, EBI-7082156;
CC       Q8TDX7; F6Y2X3: TAFAZZIN; NbExp=3; IntAct=EBI-1055945, EBI-25833693;
CC       Q8TDX7; Q13428-5: TCOF1; NbExp=3; IntAct=EBI-1055945, EBI-25832010;
CC       Q8TDX7; P48775: TDO2; NbExp=3; IntAct=EBI-1055945, EBI-743494;
CC       Q8TDX7; Q9BT49: THAP7; NbExp=3; IntAct=EBI-1055945, EBI-741350;
CC       Q8TDX7; P49746: THBS3; NbExp=3; IntAct=EBI-1055945, EBI-2530931;
CC       Q8TDX7; P42166: TMPO; NbExp=2; IntAct=EBI-1055945, EBI-395393;
CC       Q8TDX7; Q96JJ7-2: TMX3; NbExp=3; IntAct=EBI-1055945, EBI-25833898;
CC       Q8TDX7; Q9H2S6-2: TNMD; NbExp=3; IntAct=EBI-1055945, EBI-12003398;
CC       Q8TDX7; Q68CL5-3: TPGS2; NbExp=3; IntAct=EBI-1055945, EBI-9091010;
CC       Q8TDX7; Q9ULW0: TPX2; NbExp=3; IntAct=EBI-1055945, EBI-1037322;
CC       Q8TDX7; Q9NX07: TRNAU1AP; NbExp=3; IntAct=EBI-1055945, EBI-12581310;
CC       Q8TDX7; P07437: TUBB; NbExp=3; IntAct=EBI-1055945, EBI-350864;
CC       Q8TDX7; Q7Z780: U2AF1; NbExp=3; IntAct=EBI-1055945, EBI-25833730;
CC       Q8TDX7; O75317: USP12; NbExp=3; IntAct=EBI-1055945, EBI-2511507;
CC       Q8TDX7; Q96EF9: ZHX1-C8orf76; NbExp=3; IntAct=EBI-1055945, EBI-25830993;
CC       Q8TDX7; Q9BQ29; NbExp=3; IntAct=EBI-1055945, EBI-22013570;
CC       Q8TDX7-1; Q96P20-1: NLRP3; NbExp=6; IntAct=EBI-16193799, EBI-14029575;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q9ES74}. Cytoplasm
CC       {ECO:0000269|PubMed:17586473}. Cytoplasm, cytoskeleton, spindle pole
CC       {ECO:0000269|PubMed:19414596}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:17101132,
CC       ECO:0000269|PubMed:17586473}. Note=Present at centrosome throughout the
CC       cell cycle (PubMed:17586473). Also detected at spindle midzone of the
CC       anaphase cells and eventually concentrates at the midbody
CC       (PubMed:17586473). Interaction with ANKS3 prevents its translocation to
CC       the nucleus (By similarity). {ECO:0000250|UniProtKB:Q9ES74,
CC       ECO:0000269|PubMed:17586473}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8TDX7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8TDX7-2; Sequence=VSP_041243, VSP_041244;
CC   -!- TISSUE SPECIFICITY: Highly expressed in lung, muscle, testis, brain,
CC       heart, liver, leukocyte and spleen. Lower expression in ovary, prostate
CC       and kidney. No expression seen in small intestine.
CC       {ECO:0000269|PubMed:11701951}.
CC   -!- DOMAIN: Displays an autoinhibited conformation: Tyr-97 side chain
CC       points into the active site, interacts with the activation loop, and
CC       blocks the alphaC helix. The autoinhibitory conformation is released
CC       upon binding with NEK9. {ECO:0000269|PubMed:19941817}.
CC   -!- DOMAIN: The NTE (N-terminal extension) motif is a structural component
CC       of the catalytic domain and thus contributes to activity.
CC       {ECO:0000269|PubMed:19941817}.
CC   -!- PTM: Phosphorylation at Ser-195 required for its activation.
CC       {ECO:0000269|PubMed:12840024}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr
CC       protein kinase family. NIMA subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB062450; BAB85632.1; -; mRNA.
DR   EMBL; CK819069; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC093419; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC093561; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471067; EAW91294.1; -; Genomic_DNA.
DR   CCDS; CCDS1394.1; -. [Q8TDX7-1]
DR   RefSeq; NP_598001.1; NM_133494.2. [Q8TDX7-1]
DR   PDB; 2WQM; X-ray; 2.10 A; A=1-302.
DR   PDB; 2WQN; X-ray; 2.30 A; A=1-302.
DR   PDB; 5DE2; X-ray; 2.78 A; A/B=1-302.
DR   PDB; 6NPY; EM; 3.80 A; B=1-302.
DR   PDB; 6S73; X-ray; 3.50 A; A/B/C/D=1-302.
DR   PDB; 6S75; X-ray; 3.30 A; A/B/C/D=1-302.
DR   PDB; 6S76; X-ray; 3.38 A; A/B/C/D=1-302.
DR   PDBsum; 2WQM; -.
DR   PDBsum; 2WQN; -.
DR   PDBsum; 5DE2; -.
DR   PDBsum; 6NPY; -.
DR   PDBsum; 6S73; -.
DR   PDBsum; 6S75; -.
DR   PDBsum; 6S76; -.
DR   AlphaFoldDB; Q8TDX7; -.
DR   SMR; Q8TDX7; -.
DR   BioGRID; 126636; 59.
DR   DIP; DIP-50780N; -.
DR   IntAct; Q8TDX7; 187.
DR   MINT; Q8TDX7; -.
DR   STRING; 9606.ENSP00000356355; -.
DR   BindingDB; Q8TDX7; -.
DR   ChEMBL; CHEMBL4849; -.
DR   DrugCentral; Q8TDX7; -.
DR   TCDB; 1.I.1.1.3; the nuclear pore complex (npc) family.
DR   GlyGen; Q8TDX7; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q8TDX7; -.
DR   MetOSite; Q8TDX7; -.
DR   PhosphoSitePlus; Q8TDX7; -.
DR   BioMuta; NEK7; -.
DR   DMDM; 37537965; -.
DR   CPTAC; CPTAC-1621; -.
DR   EPD; Q8TDX7; -.
DR   jPOST; Q8TDX7; -.
DR   MassIVE; Q8TDX7; -.
DR   MaxQB; Q8TDX7; -.
DR   PaxDb; Q8TDX7; -.
DR   PeptideAtlas; Q8TDX7; -.
DR   PRIDE; Q8TDX7; -.
DR   ProteomicsDB; 74364; -. [Q8TDX7-1]
DR   ProteomicsDB; 74365; -. [Q8TDX7-2]
DR   Antibodypedia; 20630; 370 antibodies from 36 providers.
DR   DNASU; 140609; -.
DR   Ensembl; ENST00000367383.5; ENSP00000356353.1; ENSG00000151414.15. [Q8TDX7-2]
DR   Ensembl; ENST00000367385.9; ENSP00000356355.4; ENSG00000151414.15. [Q8TDX7-1]
DR   Ensembl; ENST00000538004.5; ENSP00000444621.1; ENSG00000151414.15. [Q8TDX7-1]
DR   GeneID; 140609; -.
DR   KEGG; hsa:140609; -.
DR   MANE-Select; ENST00000367385.9; ENSP00000356355.4; NM_133494.3; NP_598001.1.
DR   UCSC; uc001gun.5; human. [Q8TDX7-1]
DR   CTD; 140609; -.
DR   DisGeNET; 140609; -.
DR   GeneCards; NEK7; -.
DR   HGNC; HGNC:13386; NEK7.
DR   HPA; ENSG00000151414; Tissue enhanced (heart).
DR   MIM; 606848; gene.
DR   neXtProt; NX_Q8TDX7; -.
DR   OpenTargets; ENSG00000151414; -.
DR   PharmGKB; PA31551; -.
DR   VEuPathDB; HostDB:ENSG00000151414; -.
DR   eggNOG; KOG0591; Eukaryota.
DR   GeneTree; ENSGT00940000156725; -.
DR   HOGENOM; CLU_000288_63_23_1; -.
DR   InParanoid; Q8TDX7; -.
DR   OMA; MHSANIQ; -.
DR   OrthoDB; 1318335at2759; -.
DR   PhylomeDB; Q8TDX7; -.
DR   TreeFam; TF105135; -.
DR   PathwayCommons; Q8TDX7; -.
DR   Reactome; R-HSA-2980767; Activation of NIMA Kinases NEK9, NEK6, NEK7.
DR   Reactome; R-HSA-3301854; Nuclear Pore Complex (NPC) Disassembly.
DR   Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation.
DR   SignaLink; Q8TDX7; -.
DR   SIGNOR; Q8TDX7; -.
DR   BioGRID-ORCS; 140609; 17 hits in 1116 CRISPR screens.
DR   ChiTaRS; NEK7; human.
DR   EvolutionaryTrace; Q8TDX7; -.
DR   GenomeRNAi; 140609; -.
DR   Pharos; Q8TDX7; Tchem.
DR   PRO; PR:Q8TDX7; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q8TDX7; protein.
DR   Bgee; ENSG00000151414; Expressed in heart right ventricle and 206 other tissues.
DR   ExpressionAtlas; Q8TDX7; baseline and differential.
DR   Genevisible; Q8TDX7; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0000922; C:spindle pole; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0035865; P:cellular response to potassium ion; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; TAS:UniProtKB.
DR   GO; GO:0051225; P:spindle assembly; TAS:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Cytoplasm;
KW   Cytoskeleton; Kinase; Magnesium; Metal-binding; Microtubule;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..302
FT                   /note="Serine/threonine-protein kinase Nek7"
FT                   /id="PRO_0000086430"
FT   DOMAIN          34..299
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          20..33
FT                   /note="NTE motif"
FT   ACT_SITE        161
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         40..48
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         63
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   SITE            97
FT                   /note="Autoinhibitory"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         5
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         195
FT                   /note="Phosphoserine; by NEK9"
FT                   /evidence="ECO:0000269|PubMed:12840024"
FT   VAR_SEQ         67..119
FT                   /note="IFDLMDAKARADCIKEIDLLKQLNHPNVIKYYASFIEDNELNIVLELADAGD
FT                   L -> VCLLPVWERRVCALNACYFLEIIKGSESLQYMATLTNLFENLPVSHHGSFAKK
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_041243"
FT   VAR_SEQ         120..302
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_041244"
FT   VARIANT         35
FT                   /note="R -> G (in dbSNP:rs55833332)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040924"
FT   VARIANT         275
FT                   /note="I -> M (in an ovarian serous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040925"
FT   MUTAGEN         28
FT                   /note="Y->A: Significant decrease in catalytic activity;
FT                   when associated with A-31."
FT                   /evidence="ECO:0000269|PubMed:19941817"
FT   MUTAGEN         31
FT                   /note="L->A: Significant decrease in catalytic activity;
FT                   when associated with A-28."
FT                   /evidence="ECO:0000269|PubMed:19941817"
FT   MUTAGEN         33
FT                   /note="N->D: Significant decrease in catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:19941817"
FT   MUTAGEN         97
FT                   /note="Y->A: 5-fold increase in catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:19941817"
FT   MUTAGEN         97
FT                   /note="Y->F,L: Moderate increase in catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:19941817"
FT   HELIX           24..26
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   HELIX           31..33
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   STRAND          34..41
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   STRAND          43..45
FT                   /evidence="ECO:0007829|PDB:6S76"
FT   STRAND          47..53
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   TURN            54..56
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   STRAND          59..65
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   TURN            67..70
FT                   /evidence="ECO:0007829|PDB:2WQN"
FT   HELIX           73..87
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   STRAND          97..103
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   STRAND          106..112
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   STRAND          115..118
FT                   /evidence="ECO:0007829|PDB:6S75"
FT   HELIX           119..128
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   HELIX           135..154
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   HELIX           164..166
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   STRAND          167..169
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   STRAND          171..173
FT                   /evidence="ECO:0007829|PDB:6S75"
FT   STRAND          175..177
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   HELIX           205..208
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   TURN            209..211
FT                   /evidence="ECO:0007829|PDB:6S73"
FT   HELIX           215..231
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   HELIX           243..251
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   TURN            260..262
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   HELIX           265..274
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   HELIX           279..281
FT                   /evidence="ECO:0007829|PDB:2WQM"
FT   HELIX           285..299
FT                   /evidence="ECO:0007829|PDB:2WQM"
SQ   SEQUENCE   302 AA;  34551 MW;  C1FC990B34D94D4C CRC64;
     MDEQSQGMQG PPVPQFQPQK ALRPDMGYNT LANFRIEKKI GRGQFSEVYR AACLLDGVPV
     ALKKVQIFDL MDAKARADCI KEIDLLKQLN HPNVIKYYAS FIEDNELNIV LELADAGDLS
     RMIKHFKKQK RLIPERTVWK YFVQLCSALE HMHSRRVMHR DIKPANVFIT ATGVVKLGDL
     GLGRFFSSKT TAAHSLVGTP YYMSPERIHE NGYNFKSDIW SLGCLLYEMA ALQSPFYGDK
     MNLYSLCKKI EQCDYPPLPS DHYSEELRQL VNMCINPDPE KRPDVTYVYD VAKRMHACTA
     SS
//
